News Features ‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry Michael O'Riordan January 10, 2020
News Daily News Most Secondary Prevention Patients Are Eligible for Multiple Drugs Michael O'Riordan January 03, 2020